Trials / Completed
CompletedNCT03269773
Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD)
A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 197 (actual)
- Sponsor
- Kang Stem Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This is multi-center, randomized, double-blind, parallel, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of FURESTEM-AD Inj. for moderate to severe chronic atopic dermatitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | FURESTEM-AD Inj. | 0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5 mL). Treatment group: FURESTEM-AD® inj. 5.0 X 107 cells/1.5 mL |
| OTHER | Placebo | 0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5mL) |
Timeline
- Start date
- 2018-04-25
- Primary completion
- 2019-03-30
- Completion
- 2019-06-20
- First posted
- 2017-09-01
- Last updated
- 2019-09-12
Locations
11 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03269773. Inclusion in this directory is not an endorsement.